NYU Winthrop University Hospital Department of Urology
Welcome,         Profile    Billing    Logout  
 4 Trials 
7 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Katz, Aaron E
QUILT-3.032, NCT03022825: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer

May 2023 - May 2023: FDA targt action date for approval in BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ based on QUILT-3.032 study
Checkmark Accepted for review for BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ based on QUILT-3.032 study
Jul 2022 - Jul 2022: Accepted for review for BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ based on QUILT-3.032 study
Checkmark Data from QUILT-3.032 trial in combination with BCG for NMIBC at ASCO 2022
Jun 2022 - Jun 2022: Data from QUILT-3.032 trial in combination with BCG for NMIBC at ASCO 2022
More
Active, not recruiting
2/3
190
US
N-803 and BCG, N-803
ImmunityBio, Inc.
Bladder Cancer
10/24
03/29
NCT04025372: INTREPId (INTermediate Risk Erection PreservatIon Trial)

Active, not recruiting
2
234
US
Bicalutamide, GnRH Agonist, Radiation Therapy, Darolutamide
Dana-Farber Cancer Institute, Bayer, Decipher Biosciences
Prostate Cancer
10/27
03/28
QUILT-2.005, NCT02138734: A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer

Recruiting
1/2
596
US
BCG+N-803( 50mg BCG/ Instillation+ N-803( 400 μg/instillation). ), BCG( 50mg/Instillation)
ImmunityBio, Inc.
Non-muscle Invasive Bladder Cancer
12/28
12/38
Palmer, Mary
IMPACT, NCT04406389: Anticoagulation in Critically Ill Patients With COVID-19 (The Trial)

Terminated
4
14
US
Enoxaparin sodium, Lovenox, Unfractionated heparin, Sodium heparin, Fondapariniux, Arixtra, Argatroban
Weill Medical College of Cornell University
COVID-19
04/21
04/22
NEST-1, NCT05571293: Combination Immunotherapy in Colorectal Cancer

Recruiting
2
36
NA
Botensilimab, Balstilimab
Weill Medical College of Cornell University, Agenus Inc.
Colorectal Neoplasms
05/25
12/25
PANTHER, NCT05024097: A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.

Recruiting
2
43
US
Etrumadenant (AB928), Radiation therapy, FOLFOX regimen, Zimberelimab (AB122)
Weill Medical College of Cornell University, Arcus Biosciences, Inc.
Rectal Cancer
12/25
12/30
ROBIN, NCT05943210: The Radiation Oncology-Biology Integration Network () Molecular Characterization Trial (MCT) of Standard Short Course Radiotherapy for Rectal Cancer

Recruiting
N/A
25
US
Short Course Radiation Therapy (scRT), Total Mesenteric Excision (TME)
Weill Medical College of Cornell University, National Cancer Institute (NCI)
Rectal Cancer
05/28
05/28
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Katz, Aaron E
QUILT-3.032, NCT03022825: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer

May 2023 - May 2023: FDA targt action date for approval in BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ based on QUILT-3.032 study
Checkmark Accepted for review for BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ based on QUILT-3.032 study
Jul 2022 - Jul 2022: Accepted for review for BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ based on QUILT-3.032 study
Checkmark Data from QUILT-3.032 trial in combination with BCG for NMIBC at ASCO 2022
Jun 2022 - Jun 2022: Data from QUILT-3.032 trial in combination with BCG for NMIBC at ASCO 2022
More
Active, not recruiting
2/3
190
US
N-803 and BCG, N-803
ImmunityBio, Inc.
Bladder Cancer
10/24
03/29
NCT04025372: INTREPId (INTermediate Risk Erection PreservatIon Trial)

Active, not recruiting
2
234
US
Bicalutamide, GnRH Agonist, Radiation Therapy, Darolutamide
Dana-Farber Cancer Institute, Bayer, Decipher Biosciences
Prostate Cancer
10/27
03/28
QUILT-2.005, NCT02138734: A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer

Recruiting
1/2
596
US
BCG+N-803( 50mg BCG/ Instillation+ N-803( 400 μg/instillation). ), BCG( 50mg/Instillation)
ImmunityBio, Inc.
Non-muscle Invasive Bladder Cancer
12/28
12/38
Palmer, Mary
IMPACT, NCT04406389: Anticoagulation in Critically Ill Patients With COVID-19 (The Trial)

Terminated
4
14
US
Enoxaparin sodium, Lovenox, Unfractionated heparin, Sodium heparin, Fondapariniux, Arixtra, Argatroban
Weill Medical College of Cornell University
COVID-19
04/21
04/22
NEST-1, NCT05571293: Combination Immunotherapy in Colorectal Cancer

Recruiting
2
36
NA
Botensilimab, Balstilimab
Weill Medical College of Cornell University, Agenus Inc.
Colorectal Neoplasms
05/25
12/25
PANTHER, NCT05024097: A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.

Recruiting
2
43
US
Etrumadenant (AB928), Radiation therapy, FOLFOX regimen, Zimberelimab (AB122)
Weill Medical College of Cornell University, Arcus Biosciences, Inc.
Rectal Cancer
12/25
12/30
ROBIN, NCT05943210: The Radiation Oncology-Biology Integration Network () Molecular Characterization Trial (MCT) of Standard Short Course Radiotherapy for Rectal Cancer

Recruiting
N/A
25
US
Short Course Radiation Therapy (scRT), Total Mesenteric Excision (TME)
Weill Medical College of Cornell University, National Cancer Institute (NCI)
Rectal Cancer
05/28
05/28

Download Options